Thermo Fisher Scientific Inc. (TMO) Business Profile

What it does

Thermo Fisher Scientific is a science-tools, diagnostics and services company headquartered in Waltham and founded in 2006. Marc N. Casper is Chairman, President and Chief Executive Officer. Its mission is to enable customers to make the world healthier, cleaner and safer.

The company supplies the products and services used across the scientific workflow: tools for biological research, instruments for analyzing samples and materials, diagnostic tests used by laboratories, laboratory supplies, and outsourced development, clinical-research and manufacturing services for medicines. Its brands include Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.

Life Sciences Solutions sells reagents, instruments and consumables for biological and medical research, drug and vaccine discovery, biologics production, genomics and proteomics, and disease diagnosis. Analytical Instruments supplies equipment, software, consumables and services for sample analysis, chemical analysis and electron microscopy. Specialty Diagnostics provides diagnostic test kits, reagents, culture media, instruments and related products for healthcare, clinical, pharmaceutical, industrial and food-safety laboratories.

Laboratory Products and Biopharma Services combines laboratory consumables, equipment and chemicals with a distribution channel and outsourced services. Those services span pharmaceutical development, clinical trials, clinical research and commercial drug manufacturing, including small-molecule and large-molecule medicines.

How it makes money

Thermo Fisher makes money from four operating segments: Life Sciences Solutions; Analytical Instruments; Specialty Diagnostics; and Laboratory Products and Biopharma Services. The mix includes manufactured products, sourced products sold through its channels, associated consumables, software, services, and contract services for drug developers. This puts transactions at several points in a customer’s workflow, from research through clinical development and commercial manufacturing.

Many instruments are sold with related reagents, consumables, software and service needs. The diagnostics business sells test kits, reagents, culture media, instruments and associated products. The laboratory-products channel sells consumables, equipment and chemicals, including products made by Thermo Fisher, private-label products and third-party brands. The company also provides standardization and supply-chain-management services intended to reduce customer procurement costs.

The pharma-services business covers development, manufacturing and clinical-trials services, while clinical research covers integrated clinical development, analytics, site and patient-access services across Phases I-IV and peri- and post-approval work. These service businesses earn revenue as customers outsource parts of drug development and production.

In the latest reported quarter, Q3 2026 revenue was $12.14 billion, adjusted operating income was $2.97 billion and adjusted operating margin was 24.5%. Q3 reported revenue growth included 6% organic growth, a 4% contribution from acquisition and a 1% decrease from the microbiology-business divestiture. The company completed that divestiture during the quarter.

The company uses acquisitions as a primary capital-deployment method and share buybacks and dividends secondarily. In 2025, acquisitions used cash of $4.04 billion, while purchases of property, plant and equipment for capacity and capability investments used $1.52 billion.

Customers and how it sells

Thermo Fisher serves pharmaceutical and biotech companies, hospitals, clinical diagnostic laboratories, universities, research institutions, government agencies and customers in environmental, industrial, research and development, quality-control and process-control settings. Pharma and biotech is its largest end market and represents about 60.0% of revenue.

The company reaches customers through a direct sales force, customer-service professionals, electronic commerce and third-party distributors. It has approximately 14,000 sales personnel, including technical specialists. Its research and safety market channel sells a mix of Thermo Fisher-made products, private-label products and third-party brands, while its healthcare market channel serves hospitals, clinical laboratories, reference laboratories, physicians’ offices and other clinical-testing facilities.

The company operates globally. As of December 31, 2025, it employed 125,000 people: approximately 59,000 in the Americas, 22,000 in Asia-Pacific and 44,000 in Europe, the Middle East and Africa. Its operations and taxable presence extend to approximately 70 countries outside the U.S.

In Q3 2026, North America and Europe grew mid single digits, Asia-Pacific grew low double digits, and China also grew low double digits. The company reported that revenue grew in North America, Europe and Asia-Pacific during 2025 but declined in China.

Suppliers and costs

Thermo Fisher manufactures products and also sources products for its channels. Management believes it has readily available raw-material supplies for significant products from various sources, and no single supplier is material. However, certain materials or components may come from a single supplier or a limited number because of quality assurance, regulatory requirements, cost effectiveness, availability or unique design.

Input costs can move with raw-material and fuel prices. The company uses approaches including alternative materials to mitigate those fluctuations. Its cost base also includes research and development, commercial capabilities, manufacturing capacity, logistics, employee costs, facilities, acquisitions and compliance with environmental, product, safety, privacy, cybersecurity, import/export and other regulations.

The company uses its Practical Process Improvement Business System to address inflation, reduce costs and improve profitability. Its stated productivity actions include continuous-improvement methods, global sourcing, restructuring, facility consolidation and manufacturing in lower-cost regions. Charges for restructuring and related actions were approximately $0.3 billion in 2025, principally for headcount reductions and facility consolidations.

Competitive position

Thermo Fisher faces manufacturers, third-party distributors and service providers across virtually all of its markets. Competition differs by business: life-science tools and reagents, analytical instruments, diagnostics, laboratory distribution, biopharma manufacturing and clinical-research services. The company identifies technical performance, advances in technology including artificial intelligence, price/performance, differentiation, availability, reliability, breadth of capability, customer service, research programs and relative price as factors in winning business.

No individual competing company is named in the provided company disclosures. Mayo Clinic is named as a collaborator on Precure, an initiative that combines its biological samples and clinical insights with Thermo Fisher’s proteomics capabilities.

Our reading: Thermo Fisher’s breadth is a meaningful moat source because its four segments combine instruments, consumables, distribution and outsourced drug-development services that can serve customers across multiple workflow stages. [item1]

Our reading: Its installed commercial reach is a meaningful moat source: it sells through direct specialists, e-commerce and distributors, and has approximately 14,000 sales personnel. [item1]

Our reading: Product innovation and application expertise are a meaningful but contestable moat source because the company itself describes changing technology and customer demands, requiring continuing research and development. [item1, item1a]

Our reading: Patents, trade secrets, trademarks and licenses protect parts of the portfolio, but no particular patent or related group is described as essential to the company as a whole. [item1]

Growth opportunities

The company’s growth strategy has three pillars: high-impact innovation, trusted-partner status with customers and its commercial engine. It invests in research and development, capacity, capabilities and acquisitions, and its R&D work aims to develop technologies, improve existing offerings and expand applications. It also expects to continue making significant R&D expenditures.

Its growth vectors include biologics production, proteomics, genomics, electron microscopy, semiconductor research and manufacturing applications, diagnostics, laboratory distribution, pharma services and clinical research. In 2025, organic revenue growth was led by Laboratory Products and Biopharma Services and Life Sciences Solutions. The company acquired Olink Holding AB (publ) in 2024 to add proteomics capabilities and acquired a filtration and separation business from Solventum Corporation in 2025 to expand bioproduction and industrial-filtration capabilities.

The company completed the acquisition of Clario in late March 2026. Clario’s digital endpoint data solutions add to clinical insights for pharma and biotech customers. The company says the acquisition is integrating smoothly and that it is building momentum for revenue synergies in clinical development.

For 2026, the company expects revenue of $47.7 billion to $48.2 billion, representing 7% to 8% reported revenue growth over 2025, and 4% organic revenue growth. It expects adjusted earnings per share of $25.13 to $25.43 and free cash flow of $7 billion to $7.5 billion. It expects net capital expenditures of $1.9 billion to $2 billion.

Structural risks

• Demand and budgets can weaken or become cyclical in the markets Thermo Fisher serves. The company identifies risks of lower demand, longer sales cycles, order cancellations or delays, slower technology adoption, price pressure, collection difficulty and excess or obsolete inventories.

• Global operations expose the company to geopolitical uncertainty, tariffs and countermeasures, transport disruption, trade restrictions, local-supplier requirements in China, currency and cost pressures, differing labor rules and differing intellectual-property protection.

• Product competitiveness depends on developing new products, adapting to rapid technological change, responding to competitors’ launches and maintaining quality. The company’s markets have changing technology and customer demands that require continuing research and development.

• Certain materials and components are sole-sourced or available from limited sources. A disruption could cause production interruptions, delays and inefficiencies.

• Operations and offerings are subject to complex regulation covering chemicals, drugs, diagnostic and laboratory activities, environmental matters, safety, privacy, cybersecurity, AI, government contracts, imports, exports and logistics. Noncompliance can lead to fines, restrictions, penalties or contract suspension.

• The company and its third-party providers experience cyber-attacks and unauthorized-access attempts regularly, and it expects those attempts to continue.

Bottom line

Our reading

Our reading: Thermo Fisher is a diversified provider of scientific tools, laboratory supplies, diagnostics and outsourced drug-development services, with revenue opportunities across research, clinical development, manufacturing and testing workflows. [item1]

Our reading: Its business rests on a broad portfolio, global commercial channels and recurring consumable, service and outsourcing activity, while pharma and biotech accounts for about 60.0% of revenue. [item1, fact_4ffb3d9f]

Our reading: Exposure to customer funding cycles, technology change, global supply chains, regulation and concentrated end-market demand remains material. [item1, item1a]